Get started
Author

Maureen M. Lynes

Observed names: Maureen Lynes, Maureen M Lynes
ORCID: 0000-0001-6808-5109
Observed ORCID: 0000-0001-6808-5109
OpenAlex ID: A5091574158
Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease
2017 · Natalia Rodriguez-Muela, Nadia K. Litterman, et al. · Cell Reports · 55
Assays for the Identification and Prioritization of Drug Candidates for Spinal Muscular Atrophy
2014 · Jonathan J. Cherry, Dione T. Kobayashi, et al. · Assay and Drug Development Technologies · 39
Discovery of Kinesin KIF18A Inhibitor ATX020: Tactical Application of Silicon Atom Replacement
2025 · Brian A. Sparling, Hyelee Lee, et al. · ACS Medicinal Chemistry Letters · 8
The KIF18A Inhibitor ATX020 Induces Mitotic Arrest and DNA Damage in Chromosomally Instable High-Grade Serous Ovarian Cancer Cells
2025 · Jayakumar Nair, Tzu-Ting Huang, et al. · Cells · 6
PDF
Characterization of exoribonuclease XRN1 as a cancer target and identification of adenosine-3’,5’-bisphosphate as a potent enzyme inhibitor
2025 · Gordon J. Lockbaum, Maureen M. Lynes, et al. · Communications Biology · 6
PDF
Abstract B073: Characterization of selective, allosteric inhibitors of human XRN1
2023 · Gordon J Lockbaum, E. Allen Sickmier, et al. · Molecular Cancer Therapeutics · 5
Abstract 3784: Activity of the novel KIF18A inhibitor, ATX-295, is enriched in whole genome doubled ovarian cancer pre-clinical models
2025 · Maureen M. Lynes, Sanjoy Kahn, et al. · Cancer Research · 4
Abstract A163: Exoribonuclease XRN1 is a therapeutic vulnerability in tumors with intrinsically elevated type I interferon signaling
2023 · Maureen M Lynes, Sophie A Shen, et al. · Molecular Cancer Therapeutics · 2
A first-in-human study of ATX-295, an oral inhibitor of KIF18A, in patients with advanced or metastatic solid tumors, including ovarian cancer.
2026 · Judy S. Wang, Ildefonso I. Rodriguez Rivera, et al. · Journal of Clinical Oncology · 1
PDF
Abstract 5744: Robust anti-tumor activity of the novel KIF18A inhibitor, ATX-295, in preclinical models of chromosomally instable tumors
2026 · Laura Ghisolfi, Maureen M. Lynes, et al. · Cancer Research · 1
Abstract B024: Investigating a novel KIF18A inhibitor ATX020 in chromosomally instable ovarian cancer
2025 · Jayakumar R. Nair, Maureen M. Lynes, et al. · Cancer Research · 1
Abstract B070: ATX-295, a Novel KIF18A Inhibitor, as a Therapeutic in Chromosomally Instable Tumors
2026 · Sunaina Nayak, Maureen M. Lynes, et al. · Clinical Cancer Research
Abstract LB056: Inhibiting WEE1 kinase enhances sensitivity of high grade serous ovarian cancer cells to the novel KIF18A inhibitor ATX020
2026 · Jayakumar R. Nair, Tzu-Ting Huang, et al. · Cancer Research
Kinesin motor protein inhibitors as therapeutics
2026 · Maureen M. Lynes, Brian A. Sparling · Methods in enzymology on CD-ROM/Methods in enzymology
Abstract B122: Activity of the novel KIF18A Inhibitor, ATX-295, is enriched in whole genome doubled ovarian and TNBC preclinical models
2025 · Laura Ghisolfi, Maureen M. Lynes, et al. · Molecular Cancer Therapeutics
Abstract PR006: Target validation and drug discovery efforts on exoribonuclease XRN1
2024 · Maureen M. Lynes, Gordon J. Lockbaum, et al. · Molecular Cancer Therapeutics
Abstract IA024: RNA-modifying enzyme inhibitors as synthetic lethal cancer therapeutics
2024 · Serena J Silver, Maureen M. Lynes, et al. · Molecular Cancer Therapeutics
Faculty Opinions recommendation of Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice.
2013 · Brent Cochran, Maureen M Lynes · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Faculty Opinions recommendation of Stat3 activation is limiting for reprogramming to ground state pluripotency.
2010 · Brent Cochran, Maureen M Lynes · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Works count: 19
Citation count: 128
H-index: 5
I10-index: 2
Year
Topic
Type